| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16722 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2016-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_082201b64bb2374942c61cb16bc165a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94c81bb9a4e8fdb5427c4e78fca65720
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_548e9ceab28b933c3720248a90c9efb7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3d93d402ed6615be01efc2887a36e65 |
| publicationDate |
2018-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2016238966-B2 |
| titleOfInvention |
Antigen delivery platforms |
| abstract |
This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development. |
| priorityDate |
2010-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |